某“三甲”医院2009-2011年口服抗消化性溃疡药应用分析

Analysis of the Utilization of Anti-peptic Ulcer Drugs in a Third Grade Class A Hospital from 2009 to 2011

目的:评价某"三甲"医院口服抗消化性溃疡药的应用情况及趋势。方法:对某"三甲"医院2009-2011年口服抗消化性溃疡药的销售金额、用药频度(DDDs)及日均费用(DDC)等进行回顾性分析。结果:从各类药物的销售金额构成比来看,质子泵抑制剂所占比例最大,每年均在65%以上;其次是胃黏膜保护药,每年均在18%以上。从单品种药物来看,各年度销售金额排在前3位的均是雷贝拉唑、兰索拉唑、泮托拉唑。从DDDs排序来看,各年度居前列的均为雷贝拉唑、奥美拉唑和雷尼替丁。结论:该院口服抗消化性溃疡药的应用符合消化性溃疡的药物治疗原则,也代表了现代临床用药的趋势和方向,其中质子泵抑制剂占主导地位。

OBJECTIVE：To investigate the application tendency of oral anti-peptic ulcer drugs in a third grade class A hospital.METHODS：The utilization of oral anti-peptic ulcer drugs in a third grade class A hospital from 2009 to 2011 was analyzed retrospectively in respect of consumption sum,DDDs and DDC,etc.RESULTS：Proton pump inhibitors took the biggest proportion in term of constituent ratio of consumption sum,at least 65% every year;followed by gastric mucosal protective drugs,at least 18% every year.Rabeprazole,lansoprazole and pantoprazole got the first 3 place in respect of consumption sum.Rabeprazole,omeprazole and ranitidine got the front positions in the DDDs.CONCLUSION：The utilization of oral anti-peptic ulcer drugs in the hospital is in line with the principle of drug treatment of peptic ulcer,and also on behalf of the trends and directions of modern clinical medication,leading the list of which is proton pump inhibitor.